潜江永安药业股份有限公司 证券代码：002365 证券简称：永安药业 公告编号：2023-40 关于取得欧洲专利证书及印度尼西亚专利证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，潜江永安药业股份有限公司（以下简称"公司"）分别收到由欧洲专 利局及印度尼西亚共和国法律和人权事务部颁发的两项专利证书，具体内容如 下: 一、欧洲专利证书： 专利名称：一种牛磺酸母液除杂回收的方法以及除杂回收系统 专利号：EP3786153B1 专利申请日：2020 年 01 月 28 日 专利授权日：2023 年 07 月 19 日 发明人：陈勇、方锡权、刘锋、李少波 专利名称：一种牛磺酸母液除杂回收的方法以及除杂回收系统 专利号码：IDP000086363 专利申请日期：2020 年 01 月 31 日 专利授权日期：2023 年 03 月 10 日 专利权所有人：潜江永安药业股份有限公司 中华人民共和国湖北省潜江市 433100 专利有效期：从申请日开始 20 年 同时本专利后续将向欧洲各相关国家完成登记 二、印度尼西亚专利证书： 发明人：陈勇、方锡权、刘锋、 ...

证券代码： 002365 证券简称：永安药业 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2023-02 | --- | --- | --- | |------------------|-------------------------------------|------------------------------------------| | 投资者关系活动类 | □ 特定对象调研 | 分析师会议 | | 别 | □ 媒体采访 □ | 业绩说明会 | | | □ 新闻发布会 □ | 路演活动 | | | □ 现场参观 | | | | 其他（2023 | 年湖北辖区上市公司投资者网上集体接待日） | | 参与单位名称及人 | 线上参与"提高发展质量 | 切实回报股东"——2023 年湖北 | | 员姓名 | | | | 时间 | 2023 年 5 月 25 日 ( | 下午 14:30~16:35 | | | | https://ir.p5w.net）采 | | | 用网络远程的方式召开 | | | | 公司接待人员姓名 总经理：洪仁贵先生 | | | | 董秘兼财务总监：熊盛捷先生 | | ...

Financial Performance - The company's revenue for Q1 2023 was ¥311,166,729.63, a decrease of 24.51% compared to ¥412,209,105.79 in the same period last year[5] - Net profit attributable to shareholders was ¥14,983,070.77, down 70.38% from ¥50,589,943.61 year-on-year[5] - Basic earnings per share decreased by 69.19% to ¥0.0508 from ¥0.1649 in the same period last year[5] - Total profit for the period was ¥15,059,977.50, down 73.83% from ¥57,545,947.50 in the same period last year[10] - The total comprehensive income for Q1 2023 was CNY 12,798,926.77, down from CNY 49,907,047.08 in Q1 2022, a decrease of about 74.4%[23] - The net profit for Q1 2023 was CNY 13,694,733.08, down from CNY 50,083,816.82 in the same period last year, indicating a decline of about 72.7%[23] Cash Flow - The net cash flow from operating activities increased by 85.05% to ¥48,405,966.87, compared to ¥26,157,813.52 in the previous year[5] - The operating cash flow for Q1 2023 was CNY 48,405,966.87, an increase from CNY 26,157,813.52 in Q1 2022, showing a growth of approximately 84.5%[26] - The net cash flow from investment activities was -86,991,761.53 RMB, a decrease of 265.33% compared to the previous period, mainly due to an increase in financial management scale[11] - The net cash flow from financing activities was -30,082,708.33 RMB, a decrease of 438.82% compared to the previous period, primarily due to the repayment of bank loans by subsidiaries[11] - The company reported a net cash outflow from financing activities of -CNY 30,082,708.33 in Q1 2023, compared to a net inflow of CNY 8,878,793.95 in Q1 2022[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,432,265,076.91, a slight increase of 0.33% from ¥2,424,179,175.81 at the end of the previous year[5] - Cash and cash equivalents at the end of Q1 2023 were CNY 204,759,330.06, down from CNY 274,716,138.81 at the beginning of the year[20] - Total liabilities decreased to CNY 314,193,716.91 from CNY 321,173,058.41 at the beginning of the year[20] - Inventory as of March 31, 2023, was CNY 156,762,107.37, an increase from CNY 149,597,978.67 at the beginning of the year[20] Expenses - The company reported a significant decline in sales expenses, which rose by 96.96% to ¥40,395,430.67, primarily due to increased market operations and promotional efforts[10] - Total operating costs for Q1 2023 were CNY 309,419,184.44, down 13.4% from CNY 357,245,810.45 year-on-year[22] - Research and development expenses for Q1 2023 were CNY 9,951,522.52, consistent with CNY 9,935,149.46 in Q1 2022[22] Investment and Projects - The company reported a significant increase in construction in progress, which rose by 84.23% to ¥94,970,203.47, mainly due to investments in a 40,000-ton taurine project[10] - The company plans to expand its annual production capacity of taurine food additives by 40,000 tons, with an investment of 250 million RMB, and is currently progressing with safety assessments[15] - The company has signed a sales operation transfer agreement with Jamieson Laboratories Ltd., which includes a payment of 8.95 million CAD for asset transfer and support services[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,995, with no preferred shareholders having restored voting rights[12] - The largest shareholder, Chen Yong, holds 21.54% of the shares, amounting to 63,468,000 shares[12] Legal Matters - The company is actively responding to a patent infringement lawsuit filed in the U.S. and has engaged a U.S. law firm to protect its rights[16] - The company has not disclosed any related party transactions involving the top ten shareholders[12] Financial Gains and Losses - The company experienced a 39.34% decrease in investment income, amounting to ¥1,891,449.70 compared to ¥3,118,130.80 in the previous year[10] - The company reported a significant increase in financial asset fair value gains of CNY 6,545,418.74 compared to a loss of CNY 791,395.69 in the previous year[22]

股票代码：002365 股票简称：永安药业 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2023-01 | 投资者关系活动类 | □特定对象调研 □分析师会议 | | | --- | --- | --- | | 别 | □媒体采访 √业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及人 | 线上参与公司永安药业 2022 年度网上业绩说明会的投 | | | 员姓名 | 资者 | | | 时间 | 日（星期四）下午 15:00-17:00 | 2023 年 04 月 13 | | 地点 | "永安药业投资者关系"微信小程序 | | | 公司接待人员姓名 | 董事兼总经理：洪仁贵先生 | | | | 董事兼副总经理：丁红莉女士 | | | | 财务总监兼董事会秘书：熊盛捷先生 | | | | 独立董事：韩建涛先生 | | | | 潜江永安药业股份有限公司已于 2023 年 3 月 30 日 披露了 年年度报告。为使广大投资者更加全面、深 2022 | | | | 入地了解公司情况，公司举办 20 ...

潜江永安药业股份有限公司（以下简称"公司"）已于 2023 年 3 月 30 日 在中国证监会指定信息披露媒体巨潮资讯网 http://www.cninfo.com.cn 上披露 了《2022 年年度报告》及其摘要。为了让广大投资者进一步了解公司 2022 年 度经营情况等，公司定于 2023 年 4 月 13 日（星期四）下午 15:00-17:00 举办 2022 年度业绩网上说明会。 一、召开方式与时间 证券代码：002365 证券简称：永安药业 公告编号：2023-17 潜江永安药业股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 召开方式：网络远程方式 召开时间：2023 年 4 月 13 日（星期四）下午 15:00-17:00 二、 出席人员 出席本次 2022 年度业绩说明会的人员有： 公司董事兼总经理洪仁贵先生、 董事兼副总经理丁红莉女士、财务总监兼董事会秘书熊盛捷先生、独立董事韩 建涛先生。 三、投资者参与方式 本次说明会投资者可登陆"永安药业投资者关系"小程序参与互动交流， 具体参 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,462,447,548.32, a decrease of 6.58% compared to 2021[19]. - Net profit attributable to shareholders for 2022 was ¥140,349,121.41, an increase of 25.97% year-over-year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥122,356,100.74, up 33.25% from the previous year[19]. - Cash flow from operating activities for 2022 reached ¥387,279,801.68, a significant increase of 280.39% compared to 2021[19]. - Basic earnings per share for 2022 were ¥0.4762, representing a growth of 26.65% year-over-year[19]. - Total assets at the end of 2022 amounted to ¥2,424,179,175.81, reflecting a 6.05% increase from the end of 2021[19]. - The company's net assets attributable to shareholders increased by 8.12% to ¥2,017,376,834.24 by the end of 2022[19]. - The company achieved operating revenue of CNY 1,462,447,548.32, a decrease of 6.58% compared to the previous year[51]. - Operating profit increased by 15.75% to CNY 152,402,521.08, while net profit attributable to shareholders rose by 25.97% to CNY 140,349,121.41[51]. - The company reported a total revenue of ¥1,462,447,548.32, a decrease of 6.58% compared to the previous year[57]. Product Development and Market Position - The company has expanded its product offerings to include epoxy ethane and health-related products through its subsidiaries, enhancing its market presence[17]. - The company is actively involved in cross-border e-commerce and customized services for nutrition and health intervention products through its subsidiary Yong'an Kangjian[17]. - The company has maintained its focus on producing and selling liquid ammonia, sulfur, and hydrogen-related products through its subsidiary Qian'an Hydrogen Energy[17]. - The company is the largest producer of taurine globally, with an annual production capacity of 58,000 tons, holding approximately 50% market share[30]. - The company launched over 250 new products in dietary supplements, focusing on functional nutrition and health foods[49]. - The health food market in China is experiencing continuous growth, driven by an aging population and increasing consumer awareness of health[32]. - The company has developed 19 utility model patents and 1 invention patent related to its products, focusing on enhancing product performance and reducing costs[34]. - The company has plans to expand taurine production capacity and improve product quality through technological innovation to maintain market competitiveness[96]. Financial Management and Risks - The company acknowledges various risks including safety, operational, exchange rate, and management risks, as detailed in the management discussion section[4]. - The company is exposed to exchange rate risks as a significant portion of its revenue is denominated in USD, leading to potential foreign exchange losses[100]. - The company actively conducts customer credit assessments to manage accounts receivable and mitigate financial risks while maximizing operational efficiency[44]. - The company has implemented a dual sales model combining agents and direct sales to end customers, with a significant portion of taurine products exported[43]. Corporate Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the report's approval[4]. - The company has not experienced any changes in its controlling shareholder since its listing[18]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, and operations[110]. - The company has established a comprehensive internal control system, ensuring effective risk management and compliance with relevant laws and regulations[154]. - The company has implemented measures to ensure compliance with the latest regulatory requirements and improve internal governance structures[154]. - The company has established a robust investor communication strategy, including investor hotlines and online performance briefings[112]. Environmental and Social Responsibility - The company has a commitment to environmental and social responsibility, as outlined in its annual report[5]. - The company has received environmental approval for a 40,000 tons/year taurine food additive project, which was approved on November 8, 2022[35]. - The company has invested approximately 14 million yuan in environmental protection funds during the reporting period, covering online equipment operation, quarterly monitoring, and pollution control facilities operation[168]. - The company is committed to reducing carbon emissions by optimizing energy consumption and prioritizing clean energy usage[168]. - The company donated 270,000 vitamin C effervescent tablets to frontline workers in Q4 2022, demonstrating its commitment to social responsibility[178]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,004, with 699 in the parent company and 305 in major subsidiaries[136]. - The company conducted 218 training sessions in 2022, achieving a completion rate of 98.64%[139]. - The company has a structured salary management system, including annual salary and structured wage systems, to enhance employee motivation[138]. - The company has established a mechanism to ensure employee interests are aligned with shareholder interests, promoting sustainable development[148]. Legal Matters - The company is involved in multiple lawsuits, with a total amount in dispute of 420,000 CNY for one case and 50,000 CNY for another, both of which have been won by the subsidiary[200]. - The company has successfully executed and concluded a lawsuit involving 420,000 CNY, with the opposing party paying the owed amount and litigation fees[200]. - The company has engaged a U.S. law firm to handle a patent infringement lawsuit in the U.S. federal court[200]. Future Outlook and Strategic Initiatives - The company has set a performance guidance for 2023, projecting a revenue growth of 10% to 12%[123]. - The company is focused on expanding its market presence and developing new products to drive future growth[117]. - The company is exploring opportunities for mergers and acquisitions to accelerate growth and expand its product portfolio[117]. - The company plans to enhance its digital marketing strategy, aiming for a 40% increase in online sales channels[123].

Group 1: Sales and Marketing Strategy - The main sales model for Yong'an Kangjian is primarily online, with products sold through platforms like Tmall, JD.com, Taobao, and Amazon [2][3] - The company has established a partnership with Jamieson, a leading Canadian health food brand, acquiring exclusive agency rights in China [3][4] - The company is actively enhancing its cross-border e-commerce channels to expand the market for Jamieson products domestically [3][4] Group 2: Production Capacity and Pricing - The current production capacity for taurine is 34,000 tons, with a utilization rate that is linked to market prices [4][5] - The price of taurine has seen a slight recovery, influenced by raw material costs [4][5] - The fluctuation in the price of ethylene oxide has a certain impact on taurine pricing, with approximately one-third of ethylene oxide being used for in-house production [4][5] Group 3: Environmental and Regulatory Compliance - The company is increasing investments in environmental protection, with stable operation of waste treatment facilities [5] - Two environmental penalty issues are being addressed, including the relocation of a 10,000 tons/year taurine project, which is now ready for acceptance [5] - The government has initiated relocation work for residents affected by the expansion of a 40,000 tons/year ethylene oxide project, with property evaluations currently underway [5] Group 4: Employee Incentives and Corporate Governance - After going public, the company has not implemented new equity incentive plans, relying instead on performance bonuses linked to company goals to motivate employees [5]

证券代码：永安药业 证券简称：002365 潜江永安药业股份有限公司 投资者关系活动记录表 编号：2015-02 | --- | --- | --- | --- | |-------------------------|--------------------------------|--------------------------------------------------|--------------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 □媒体采访 | | | 投资者关系 | □ | 业绩说明会 □新闻发布会 □路演活动 | | | 活动类别 | □ | 现场参观 □其他 （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 天津尚道投资有限公司：张伟生 | | | | 时间 | 2015 年 5 月 11 日 | | | | 地点 | 公司会议室 | | | | 公司接待人员 | 公司董秘：吴晓波 | | | | 姓名 | 证券事务代表：邓永红 | | | | 投资者关系 | ...